Title: Goldman Sachs Analysts Bullish on Two Stocks Despite Market Concerns
The S&P 500 has recently surged beyond 5,300, surpassing some experts’ year-end targets, leading to concerns about potential overheating in the market. However, Goldman Sachs’ chief US equity strategist David Kostin believes that there may not be much more room for growth this year, citing high stock valuations and low projections for 2024 GDP and earnings growth.
Despite this cautious outlook, analysts at Goldman Sachs are optimistic about two stocks that they believe have the potential to deliver significant returns in the year ahead. Fulcrum Therapeutics and Marex Group are both rated as ‘Strong Buy’ by analysts, with compelling reasons to attract investors.
Fulcrum Therapeutics, a biopharmaceutical research company, is focused on developing new therapeutic agents for genetically defined diseases with high unmet medical needs. The company’s proprietary product development platform has identified promising drug candidates, with losmapimod being the more advanced program currently in Phase 3 clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Goldman analyst Corinne Johnson is bullish on Fulcrum Therapeutics, particularly on the potential of the losmapimod development program. She sees significant upside potential in the stock, with a price target of $15, implying a ~108% upside for the next 12 months.
Marex Group, a financial services company, provides market access, liquidity, and infrastructure services to a global client base in the energy, commodity, and financial markets. The company recently went public through an IPO and has shown strong revenue growth, with a promising outlook for future earnings.
Goldman analyst Alexander Blostein is optimistic about Marex Group’s growth potential, expecting an average EPS growth of ~20% through 2026. He rates the stock as a Buy with a price target of $33, suggesting a 61% upside potential on the one-year horizon.
Overall, both Fulcrum Therapeutics and Marex Group have received positive ratings from analysts, with strong buy consensus ratings and compelling reasons for investors to consider these stocks despite concerns about market overheating. Investors are advised to conduct their own analysis before making any investment decisions.
